Microbiome Therapies suffer setback with a Phase II Failure

02/08/2016 - 3 minutes

The hype field of the Microbiome could be taking a step back, as the most advanced program has failed to meet its primary endpoint in a Phase II trial. What does this mean for the emerging class of therapies?

As we have seen at Refresh’s Microbiome fireside chat, the field took really big steps in its recent history. In a few years, it went from an exploding area of research (highlighting surprising connections) to the creation of Biotechs focusing on the development of Microbiome-based therapies.

The expectations for the field are high – it could yield breakthroughs for many diseases, from autoimmune diseases to cancer.

Seres Therapeutics raised an impressive $134M in its IPO (on top of massive deals like the €1.7Bn collaboration with Nestlé). It also had the most advanced therapy in the field, consisting of bacterial spores (SER-109) for the treatment of recurrent Clostridium difficile infections.

Now, the results of SER-109 Phase II trials (Ecospor) are  giving a hard time to the company and the Microbiome field.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member